<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04828824</url>
  </required_header>
  <id_info>
    <org_study_id>19-2750</org_study_id>
    <nct_id>NCT04828824</nct_id>
  </id_info>
  <brief_title>Premature Discontinuation of Contraceptive Implants</brief_title>
  <official_title>Reduction of Premature Discontinuation of Contraceptive Implants by Advance Provision of an OCP-based Participant Intervention: Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare rates of etonogestrel implant discontinuation in implant initiators who are given&#xD;
      advance provision of combined oral contraceptive pills (COCs) and a bleeding rescue regimen&#xD;
      (COCR intervention) to participants given standard counseling (comparator).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective:&#xD;
&#xD;
      To compare rates of etonogestrel implant discontinuation in implant initiators who are given&#xD;
      advance provision of combined oral contraceptive pills (COCs) and a bleeding rescue regimen&#xD;
      (COCR intervention) to participants given standard counseling (comparator).&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To determine if participants initiating the contraceptive implant who are also provided COCR&#xD;
      are more likely than participants receiving standard counseling to:&#xD;
&#xD;
        1. report higher levels of satisfaction with their contraceptive implant at one year&#xD;
           following initiation&#xD;
&#xD;
        2. require less clinical follow-up and clinical resources in the year following initiation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Implant Continuation</measure>
    <time_frame>12 months post-insertion</time_frame>
    <description>We will assess continuation of use of the contraceptive implant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with contraceptive implant</measure>
    <time_frame>3, 6, and 12 months post-insertion</time_frame>
    <description>We will assess satisfaction with bleeding profile and overall satisfaction using a Likert scale (&quot;very satisfied&quot;, &quot;somewhat satisfied&quot; and &quot;not satisfied&quot;).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Implant-related health care interactions</measure>
    <time_frame>within 12 months of insertion</time_frame>
    <description>We will assess the number of healthcare interactions (phone calls, visits, messages, prescription refills) that are related to the use of the contraceptive implant or oral contraceptives dispensed in this study using the electronic medical record system.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Contraception Behavior</condition>
  <arm_group>
    <arm_group_label>COCR Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in the COCR arm will receive three packs of combined oral contraceptive pills (35mcg ethinyl estradiol/norgestimate) and a specific protocol for their use for bothersome bleeding.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in the SC arm will be offered care according to our standardized protocol, which may include STI testing, reassurance and monitoring, prescription of COCs if desired, or removal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethinyl Estradiol / Norgestimate Oral Tablet</intervention_name>
    <description>Those who desire COCs as an intervention are prescribed (over the phone) or given (in person) 3 packs of COCs. They are told to take one pill per day until the first pack is complete and save the remaining 2 packs for possible future use.</description>
    <arm_group_label>COCR Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. You are between ages of 14 to 22.9 years.&#xD;
&#xD;
          2. Started etonogestrel implant for the first time and have never used the implant&#xD;
             before.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. There is any contraindication to estrogen containing birth control.&#xD;
&#xD;
          2. Desire of pregnancy in next 12 months.&#xD;
&#xD;
          3. Plans to move from the area in next 12 months and is not able to come to the clinic.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>23 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeanelle Sheeder, PhD</last_name>
    <phone>(303) 724-2272</phone>
    <email>jeanelle.sheeder@cuanschutz.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emily Graves</last_name>
    <phone>303-724-3514</phone>
    <email>EMILY.GRAVES@CUANSCHUTZ.EDU</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Graves</last_name>
      <phone>303-724-3514</phone>
      <email>EMILY.GRAVES@CUANSCHUTZ.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Morgan Pena</last_name>
      <email>MORGAN.PENA@CUANSCHUTZ.EDU</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Norgestimate</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Estradiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

